Format

Send to

Choose Destination
Chem Res Toxicol. 2015 Oct 19;28(10):1914-25. doi: 10.1021/acs.chemrestox.5b00103. Epub 2015 Sep 15.

Integrating High-Dimensional Transcriptomics and Image Analysis Tools into Early Safety Screening: Proof of Concept for a New Early Drug Development Strategy.

Author information

1
Janssen R&D , Turnhoutseweg 30, 2340 Beerse, Belgium.

Abstract

During drug discovery and development, the early identification of adverse effects is expected to reduce costly late-stage failures of candidate drugs. As risk/safety assessment takes place rather late during the development process and due to the limited ability of animal models to predict the human situation, modern unbiased high-dimensional biology readouts are sought, such as molecular signatures predictive for in vivo response using high-throughput cell-based assays. In this theoretical proof of concept, we provide findings of an in-depth exploration of a single chemical core structure. Via transcriptional profiling, we identified a subset of close analogues that commonly downregulate multiple tubulin genes across cellular contexts, suggesting possible spindle poison effects. Confirmation via a qualified toxicity assay (in vitro micronucleus test) and the identification of a characteristic aggregate-formation phenotype via exploratory high-content imaging validated the initial findings. SAR analysis triggered the synthesis of a new set of compounds and allowed us to extend the series showing the genotoxic effect. We demonstrate the potential to flag toxicity issues by utilizing data from exploratory experiments that are typically generated for target evaluation purposes during early drug discovery. We share our thoughts on how this approach may be incorporated into drug development strategies.

PMID:
26313431
DOI:
10.1021/acs.chemrestox.5b00103
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center